Network meta-analysis of 9 RCTs in moderate-to-severe hidradenitis suppurativa: bimekizumab ranked most efficacious at weeks 12-16, with higher odds of HiSCR50 response vs secukinumab Q4W (OR 1.69) among mainly biologic-naive patients. Safety was not assessed.
Meta-analysisn = 9 trials
Naik et al. Short-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: A systematic review and NMA